Tau-targeting therapies for Alzheimer disease: current status and future directions

EE Congdon, C Ji, AM Tetlow, Y Jiang… - Nature Reviews …, 2023 - nature.com
Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

R Ossenkoppele, R van der Kant… - The Lancet …, 2022 - thelancet.com
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

R Ossenkoppele, A Pichet Binette, C Groot, R Smith… - Nature medicine, 2022 - nature.com
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications

F Gonzalez-Ortiz, PR Kac, WS Brum… - Molecular …, 2023 - Springer
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

Microglial activation and tau propagate jointly across Braak stages

TA Pascoal, AL Benedet, NJ Ashton, MS Kang… - Nature medicine, 2021 - nature.com
Compelling experimental evidence suggests that microglial activation is involved in the
spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the …

Advances in the development of new biomarkers for Alzheimer's disease

TO Klyucherev, P Olszewski, AA Shalimova… - Translational …, 2022 - Springer
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …

Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease

H Zhang, W Wei, M Zhao, L Ma, X Jiang… - … journal of biological …, 2021 - pmc.ncbi.nlm.nih.gov
Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial

E Teng, PT Manser, K Pickthorn, F Brunstein… - JAMA …, 2022 - jamanetwork.com
Importance Neurofibrillary tangles composed of aggregated tau protein are one of the
neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease …

[HTML][HTML] Neuropathology of Alzheimer's disease

JA Trejo-Lopez, AT Yachnis, S Prokop - Neurotherapeutics, 2022 - Elsevier
The key pathological hallmarks—extracellular plaques and intracellular neurofibrillary
tangles (NFT)—described by Alois Alzheimer in his seminal 1907 article are still central to …

[HTML][HTML] Innate immune cell death in neuroinflammation and Alzheimer's disease

Y Rajesh, TD Kanneganti - Cells, 2022 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder molecularly characterized by the
formation of amyloid β (Aβ) plaques and type 2 microtubule-associated protein (Tau) …